Monte Rosa Therapeutics’ plan to develop a molecular glue degrader in a wide range of cancers has come unstuck. | Monte Rosa ...

The researchers showed that the molecule UM171 works as a glue that can trigger the breakdown of the CoREST complex, an organizing system that controls access to genes. UM171 works by engaging ...

To achieve that kind of control, Choudhary and his colleagues added a special response element to the Cas9 enzyme and introduced a drug called pomalidomide, which acts as a molecular glue to bring ...

In March 2025, Magnet Biomedicine formed a partnership and licensing agreement with Eli Lilly to identify, develop, and market oncology-focused molecular glue therapeutics. In January 2025 ...

Takeda Pharmaceuticals & Degron Therapeutics (May 2024) – Developing novel molecular glue degraders for oncology, neuroscience, and inflammatory diseases. NEOsphere Biotechnologies & Kymera ...

the latest techniques for molecular glue drug discovery, and their application in the treatment of diseases. This ACS Webinar is moderated by Angela Zhou, Information Scientist at CAS and is ...

Unmet needs, market barriers, and future trends in targeted protein degradation. Takeda Pharmaceuticals & Degron Therapeutics (May 2024) – Developing novel molecular glue degraders for oncology, ...